KOL Views: Where will BMS’s Zeposia fit in the sparser environs of ulcerative colitis

Detailed data from the Phase III True North trial presented this week suggest that Bristol Myers Squibb’s Zeposia (ozanimod) – approved but facing a lot of competition in multiple sclerosis (MS) – will have a definite role to play in treating ulcerative colitis (UC). However, questions remain about where the oral S1P receptor modulator will fit in against more established injectable biologics and what kind of competition it can expect from other classes closing in on the market, most notably JAK inhibitors.

To provide FirstWord readers with rapid feedback on the True North results and what they suggest about Zeposia’s role in UC, we are hosting an expert call with a key opinion leader (KOL) late this week or early next week.

Key topics that will be discussed during the call, among other things… what drugs do you currently prescribe most often to patients with moderate-to-severe UC; after it was reported in June that Zeposia hit the co-primary endpoints of True North, what were your biggest questions coming into this week’s presentation; what stood out most about the detailed True North results; do you think the data are strong enough to support approval of Zeposia; how does Zeposia’s risk/benefit profile compare to the injectable biologics on the market for UC; how does the drug compare to what we have seen from JAK inhibitors in clinical testing for UC; does Zeposia have front-line potential; where do you see Zeposia fitting into the treatment paradigm; will Zeposia’s first-to-market advantage likely give it the upper hand among S1P receptor modulators or is there a chance for a fast-following programme to leapfrog; did anything stand out to you about the detailed results from the Phase IIb/III SELECTION trial of Jyseleca (filgotinib) from Gilead Sciences and Galapagos; where do you see JAK inhibitors like Jyseleca and AbbVie’s Rinvoq (upadacitinib) fitting into the UC treatment paradigm; and does Zeposia’s success in True North increase your confidence it will work in Crohn’s disease?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the development and commercialisation of UC therapies.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.